Stack

Tesamorelin

Also known as Egrifta

What it is: Growth hormone-releasing hormone analog
What it does: Stimulates endogenous growth hormone release
Status: Approved for one indication
Evidence: Moderate. Human clinical use exists; other uses are limited.
Uses: HIV-associated lipodystrophy; body composition research

Caution. Not a general-purpose fat-loss drug.

Summary

Tesamorelin is a synthetic GHRH analog that increases pulsatile GH and IGF-1 secretion, improving visceral adipose tissue in HIV-associated lipodystrophy. It has focused randomized trial support for this indication, but is not approved for general obesity or anti-aging. Effects are modest outside the lipodystrophy population, and it requires careful patient selection.

Checked Jul 15, 2026.

Keep a record of Tesamorelin in Stack

Stack logs each dose you take, tracks what is left in the vial or bottle and shows how you kept to your plan. It records what you choose and does not recommend anything. Everything stays on your phone, with no account.

Get Stack on Google Play Peptide reconstitution calculator

More peptides

SermorelinExperimental · low evidence CJC-1295 with DACExperimental · low evidence CJC-1295 without DACExperimental · low evidence IpamorelinExperimental · low evidence NAD+Experimental · moderate evidence

This entry summarises published information in plain language. It is not medical advice, a dosing recommendation or a substitute for a qualified healthcare professional. Many peptides are not approved for human use, and legal status varies by country. Check anything you rely on against primary sources.